- Language: English
- 381 Pages
- Published: October 2012
- Region: Global
Cote d'Ivoire Pharmaceuticals and Healthcare Report Q3 2012
- Published: June 2012
- 49 pages
- Business Monitor International
The Cote d'Ivoire Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Cote d'Ivoire's pharmaceuticals and healthcare industry.
BMI View: In keeping with President Alassane Ouatarra's promise to prioritise primary healthcare provision, following Côte d'Ivoire's civil war in 2011, new data show pharmaceuticals imports that year grew, albeit slowly, broadly in line with BMI's forecast. Healthcare and pharmaceuticals spending as a percentage of GDP increased slightly, but we expect muted growth over the medium term, which is disappointing given the country's potential. One sector that will do well is medical device imports, which will increase in order to replace the equipment that was looted from hospitals during the civil war.
Headline Expenditure Projections
- Pharmaceuticals: XOF170.3bn (US$360mn) in 2011 to XOF181.1bn (US$370mn) in 2012; +6.4% in local currency terms and +2.6% in US dollar terms. Historic data revised up moderately from Q112 due to new imports data.
- Healthcare: XOF577.9bn (US$1.22bn) in 2011 to XOF609.1bn (US$1.24bn) in 2012; +5.4% in local currency terms and +1.7% in US dollar terms. Forecast revised downwards slightly from Q212 due to new historic data.
- Medical Devices: XOF19.25bn (US$41mn) in 2011 to XOF20.69bn (US$42mn) in 2012; +7.5% in local currency terms and +3.7% in US dollar terms.
Risk/Reward Rating: In Q312, Côte d’Ivoire has moved off the bottom of BMI’s RRRs for the MEA region, although its overall score remains at 28.0 out of 100, significantly below the regional average of 44.5. Sudan has slipped below Côte d'Ivoire in terms of attractiveness for drugmakers due to the continued deterioration in its political environment. Furthermore, with Côte d'Ivoire returning to some semblance of stability and the removal of the mainly ineffectual universal free healthcare, its RRR score could improve in future.
Key Trends And Developments - Côte d'Ivoire's fight against leprosy has been suffering due to lack of funding, IRIN has reported. Health practitioners said the country has lost expertise in terms of detection and treatment of the disease after a leprosy programme was consistently underfunded during the 2002-2007 civil war and political turmoil in 2011. Alain de Kersabiec, the Côte d'Ivoire and Benin representative for French NGO the Follereau Foundation, said funding declined to 30% of the original allocation as the government and donors de-prioritised leprosy over the decade. The leprosy prevalence rate was 0.36% in Côte d'Ivoire in 2009.
- New pharmaceuticals imports data and healthcare expenditure figures for 2011 from UN Comtrade and the World Healthcare Organisation (WHO) were slightly better than BMI had forecast, resulting in a small increase to our pharmaceuticals expenditure forecast for Côte d'Ivoire.
BMI Economic View: The economic recovery in Côte d'Ivoire is accelerating as the traditional economic engine of Francophone Africa recovers from its 2010-2011 post-election violence. We are now predicting real GDP growth of 8.1% in 2012 and sustained growth of between 4% and 5% until 2021.The development of new export industries, strong consumer spending growth, and a massive increase in investment will support long-term expansion that is substantially above the sclerotic 0.5% average recorded from 2001-2011.
BMI Political View: Violence following Côte d'Ivoire's 2010 election killed over 3,000 people, but one year after the arrest of former president Laurant Gbagbo, we see many reasons to be positive about the country's political development. While the situation is still fragile, BMI predicts a gradual return to political stability SHOW LESS READ MORE >
Executive Summary 5
Pharmaceuticals Risk/Reward Ratings 7
PHARMACEUTICALS & HEALTHCARE Q312 RISK/REWARD RATINGS 8
Côte D’Ivoire – Market Overview 14
Table: Côte d’Ivoire’s Millennium Development Goals 15
Regulatory Regime 25
Pharmacovigilance (PV) 26
Industry Forecast Scenario 28
Overall Market Forecast 28
Table: Pharmaceuticals Sales Indicators 2008-2016 30
Key Growth Drivers – Industry 31
Table: Healthcare Expenditure Indicators 2008-2016 33
Table: Healthcare Governmental Indicators 2008-2016 33
Table: Healthcare Private Indicators 2008-2016 34
Key Growth Drivers – Macroeconomic 35
Demographic Outlook 39
Côte d'Ivoire's Population By Age Group, 1990-2020 ('000) 40
Côte d'Ivoire's Population By Age Group, 1990-2020 (% of total) 40
Côte d'Ivoire's Key Population Ratios, 1990-2020 41
Côte d'Ivoire's Rural And Urban Population, 1990-2020 42
BMI Methodology 45
How We Generate Our Pharmaceuticals Industry Forecasts 45
Pharmaceuticals Risk/Reward Ratings Methodology 46
Ratings Overview 46
Table: Pharmaceuticals Risk/Reward Indicators 47
Table: Weighting Of Components 48